Innovation in Crohn's disease
Unique technology to help you understand the cause of your Crohn's disease
Get your unique test
There's mounting evidence that a bacterial infection plays a role in causing Crohn's disease. We have developed a unique test to see the bacterium down the microscope. With a simple blood sample you can finally find out what causes your condition.
For $250 your sample is tested and results provided.
Diagnosing and treating Crohn's disease
Crohn’s disease is currently diagnosed by a limited range of expensive and invasive in-patient tests (endoscopy and biopsy) or by the observation of non-specific diagnostic markers.
Current routinely available blood tests are nonspecific and variable being focused on the symptoms rather than the cause of the disease.
Current available treatments are limited to immunosuppressive and anti-inflammatory drugs and surgery, which are focused on mitigation of symptoms rather than directed therapies for treatment and cure.
Pharmaceutical companies are developing antibacterial treatments for Crohn's but the target organism for these is unclear.
Our technology and test
Otakaro Pathways has developed technology relating to Crohn’s disease that is unique in the world with applications in diagnosis, treatment development and monitoring, which can be applied to a broader range of auto-immune diseases.
Specifically we have developed innovative methods to identify the bacteria that we believe is the trigger organism for Crohn’s disease.
Using these unique and patented methods we offer a unique test to anyone in the world to support the diagnosis of Crohn’s disease, which will equip them with information to have an informed discussion with their clinician so to assess appropriate treatment options.
About Crohn’s disease
Crohn’s disease is one of a class of diseases called inflammatory bowel diseases (IBD). It is a condition of chronic inflammation and symptoms vary for each individual. Crohn’s can potentially relate to any location of the gastrointestinal tract, but it often affects the ileum and the start of the colon.
An estimated 4 million people worldwide suffer from this debilitating disease.
In New Zealand alone the pharmaceutical funding agency Pharmac spent $15.4 million in year ending 2015 on the primary treatment option for Crohn’s disease for New Zealand citizens.
Currently, there is no acknowledged cause of Crohn’s disease. However, Otakaro Pathways, and many others in this field have mounting evidence that a bacterial infection plays a key role.